Literature DB >> 12502785

The role of neutralizing antibodies for mouse mammary tumor virus transmission and mammary cancer development.

Daniela Finke1, Sanjiv A Luther, Hans Acha-Orbea.   

Abstract

Mouse mammary tumor virus (MMTV) infection establishes chronic germinal centers and a lifelong neutralizing Ab response. We show that removal of the draining lymph node after establishment of the germinal center reaction led to complete loss of neutralizing Abs despite comparable infection levels in peripheral lymphocytes. Importantly, in the absence of neutralization, only the exocrine organs mammary gland, salivary gland, pancreas, and skin showed strikingly increased infection, resulting in accelerated mammary tumor development. Induction of stronger neutralization did not influence chronic infection levels of peripheral lymphoid organs but strongly inhibited mammary gland infection and virus transmission to the next generation. Taken together, we provide evidence that a tight equilibrium in virus neutralization allows limited infection of exocrine organs and controls cancer development in susceptible mouse strains. These experiments show that a strong neutralizing Ab response induced after infection is not able to control lymphoid MMTV infection. Strong neutralization, however, is capable of blocking amplification of mammary gland infection, tumor development, and virus transmission to the next generation. The results also indicate a role of neutralization in natural resistance to MMTV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12502785      PMCID: PMC140926          DOI: 10.1073/pnas.0134988100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Massive mammary gland infection and pregnancy-dependent mammary tumor development in mice infected neonatally with mouse mammary tumor virus (SW) but not in mice infected as adults, despite a dramatic local response.

Authors:  M Papiernik; A C Waché; C Pontoux; B Nabarra
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

2.  Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis.

Authors:  K L Tyler; M A Mann; B N Fields; H W Virgin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Concerted activation of two potential proto-oncogenes in carcinomas induced by mouse mammary tumour virus.

Authors:  G Peters; A E Lee; C Dickson
Journal:  Nature       Date:  1986 Apr 17-23       Impact factor: 49.962

4.  Intervention of T-cells in transportation of mouse mammary tumor virus (milk factor) to mammary gland cells in vivo.

Authors:  A Tsubura; M Inaba; S Imai; A Murakami; N Oyaizu; R Yasumizu; Y Ohnishi; H Tanaka; S Morii; S Ikehara
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

5.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome.

Authors:  R Nusse; H E Varmus
Journal:  Cell       Date:  1982-11       Impact factor: 41.582

6.  Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system.

Authors:  B Dietzschold; M Kao; Y M Zheng; Z Y Chen; G Maul; Z F Fu; C E Rupprecht; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

7.  Transgenic mouse mammary tumor virus superantigen expression prevents viral infection.

Authors:  T V Golovkina; A Chervonsky; J P Dudley; S R Ross
Journal:  Cell       Date:  1992-05-15       Impact factor: 41.582

8.  Tissue distribution of mouse mammary tumor virus (MMTV) antigens and new endogenous MMTV loci in Japanese laboratory mouse strains.

Authors:  W Wajjwalku; M Takahashi; O Miyaishi; J Lu; K Sakata; T Yokoi; S Saga; M Imai; M Matsuyama; M Hoshino
Journal:  Jpn J Cancer Res       Date:  1991-12

9.  Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus.

Authors:  W Held; A N Shakhov; S Izui; G A Waanders; L Scarpellino; H R MacDonald; H Acha-Orbea
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus.

Authors:  G A Waanders; A N Shakhov; W Held; O Karapetian; H Acha-Orbea; H R MacDonald
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more
  5 in total

1.  Neutralizing Antibody Responses to Viral Infections Are Linked to the Non-classical MHC Class II Gene H2-Ob.

Authors:  Lisa K Denzin; Aly A Khan; Francesca Virdis; Jessica Wilks; Melissa Kane; Helen A Beilinson; Stanislav Dikiy; Laure K Case; Derry Roopenian; Michele Witkowski; Alexander V Chervonsky; Tatyana V Golovkina
Journal:  Immunity       Date:  2017-08-15       Impact factor: 31.745

2.  Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle.

Authors:  M Mpandi; L A Otten; C Lavanchy; H Acha-Orbea; D Finke
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Genetic Control of Neonatal Immune Tolerance to an Exogenous Retrovirus.

Authors:  Emily Cullum; Stanislav Dikiy; Helen A Beilinson; Melissa Kane; Alessandra Veinbachs; Vera M Beilinson; Lisa K Denzin; Alexander Chervonsky; Tatyana Golovkina
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

4.  Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens.

Authors:  Sanchita Bhadra; Mary M Lozano; Shelley M Payne; Jaquelin P Dudley
Journal:  PLoS Pathog       Date:  2006-12       Impact factor: 6.823

5.  MHC Class II Presentation Is Affected by Polymorphism in the H2-Ob Gene and Additional Loci.

Authors:  Emily Cullum; Austin M Graves; Vera L Tarakanova; Lisa K Denzin; Tatyana Golovkina
Journal:  J Immunol       Date:  2021-06-16       Impact factor: 5.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.